Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-03-05

FDA Approved: ESCITALOPRAM — Supplemental Application (SOLCO HEALTHCARE US, LLC)

View source ↗

Summary

The FDA granted a supplemental approval for escitalopram (generic) from Solco Healthcare US, LLC under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Escitalopram (escitalopram)

Snippet

SUPPL AP for ESCITALOPRAM (ESCITALOPRAM)